Abstract
We report the case of an elderly patient suffering for about 20 years of hypertensive cardiac hypertrophy, carotid and peripheral vasculopathy. The patient, initially treated with oral anticoagulant therapy (dicumarol) due to relapsing atrial fibrillation, is an example of long-term use of dabigatran, dictated by safety concern in a patient at high risk of bleeding: as demonstrated by the RE-LY trial, dabigatran 110 mg / day has a preventive effect on cerebral events similar warfarin but with a lower incidence of bleeding. In this case, at high risk both thrombotic and hemorrhagic, the choice of dabigatran was successful in the long term (Cardiology).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
